Evercore ISI Issues Pessimistic Forecast for Danaher (NYSE:DHR) Stock Price

Danaher (NYSE:DHR - Free Report) had its price objective cut by Evercore ISI from $230.00 to $226.00 in a report published on Tuesday,Benzinga reports. They currently have an outperform rating on the conglomerate's stock.

A number of other brokerages have also commented on DHR. Royal Bank Of Canada reissued an "outperform" rating and issued a $250.00 price objective on shares of Danaher in a research report on Wednesday, April 23rd. Wolfe Research decreased their price objective on shares of Danaher from $275.00 to $220.00 and set an "outperform" rating on the stock in a report on Monday, April 7th. Leerink Partners raised their price target on shares of Danaher from $225.00 to $230.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 23rd. Robert W. Baird decreased their target price on shares of Danaher from $231.00 to $225.00 and set an "outperform" rating on the stock in a report on Wednesday, April 23rd. Finally, JPMorgan Chase & Co. decreased their target price on shares of Danaher from $280.00 to $260.00 and set an "overweight" rating on the stock in a report on Tuesday, April 22nd. Three research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $248.43.

Danaher Price Performance

Shares of NYSE:DHR traded down $0.71 on Tuesday, hitting $204.80. The stock had a trading volume of 2,369,010 shares, compared to its average volume of 3,504,283. The firm's 50 day moving average price is $196.05 and its 200-day moving average price is $206.47. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.43. Danaher has a twelve month low of $171.00 and a twelve month high of $281.70. The company has a market capitalization of $146.57 billion, a price-to-earnings ratio of 39.77, a price-to-earnings-growth ratio of 2.89 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.26. Danaher had a net margin of 15.81% and a return on equity of 10.80%. The firm had revenue of $5.74 billion during the quarter, compared to analysts' expectations of $5.58 billion. On average, equities research analysts predict that Danaher will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.63%. Danaher's dividend payout ratio is currently 24.85%.

Insider Buying and Selling at Danaher

In other Danaher news, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the sale, the chairman directly owned 3,105,808 shares in the company, valued at $611,036,665.92. The trade was a 28.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Christopher Paul Riley sold 15,805 shares of the business's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the sale, the executive vice president owned 15,179 shares of the company's stock, valued at approximately $3,005,442. This represents a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 11.10% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Fortis Capital Advisors LLC boosted its holdings in Danaher by 1.3% during the 4th quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate's stock valued at $914,000 after acquiring an additional 50 shares during the period. Fayez Sarofim & Co raised its holdings in Danaher by 0.6% in the fourth quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock valued at $1,902,000 after acquiring an additional 50 shares in the last quarter. Coastal Bridge Advisors LLC raised its holdings in Danaher by 4.8% in the fourth quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock valued at $252,000 after acquiring an additional 50 shares in the last quarter. Perennial Investment Advisors LLC boosted its position in shares of Danaher by 2.2% during the 4th quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate's stock worth $538,000 after acquiring an additional 51 shares in the last quarter. Finally, Sound View Wealth Advisors Group LLC boosted its holdings in Danaher by 3.1% in the fourth quarter. Sound View Wealth Advisors Group LLC now owns 1,739 shares of the conglomerate's stock valued at $399,000 after purchasing an additional 52 shares in the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.